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Abstract
The importance of the ubiquitin-proteasome pathway to cellular function has brought it to the fo-
refront in the search for new anticancer therapies. The ubiquitin-proteasome pathway has proven 
promising in targeting various human cancers. The approval of the proteasome inhibitor bortezo-
mib for clinical treatment of relapsed/refractory multiple myeloma and mantle cell lymphoma has 
validated the ubiquitin-proteasome as a rational target. Bortezomib has shown positive results in 
clinical use but some toxicity and side effects, as well as resistance, have been observed, indicating 
that further development of novel, less toxic drugs is necessary. Because less toxic drugs are necessa-
ry and drug development can be expensive and time-consuming, using existing drugs that can target 
the ubiquitin-proteasome pathway in new applications, such as cancer therapy, may be effective in 
expediting the regulatory process and bringing new drugs to the clinic. Toward this goal, previously 
approved drugs, such as disulfiram, as well as natural compounds found in common foods, such as 
green tea polyphenol (-)-EGCG and the flavonoid apigenin, have been investigated for their possi-
ble proteasome inhibitory and cell death inducing abilities. These compounds proved quite promi-
sing in preclinical studies and have now moved into clinical trials, with preliminary results that are 
encouraging. In addition to targeting the catalytic activity of the proteasome pathway, upstream 
regulators, such as the 19S regulatory cap, as well as E1, E2, and E3, are now being investigated as 
potential drug targets. This review outlines the development of novel proteasome inhibitors from 
preclinical to clinical studies, highlighting their abilities to inhibit the tumor proteasome and indu-
ce apoptosis in several human cancers.
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Ubiquitin-proteasome pathway
The ubiquitin-proteasome pathway (UPP) is critical to normal cellular function and, in 2004, the Nobel 
Prize in Chemistry was awarded to its discoverers [1,2]. The major responsibility of the ubiquitin-
proteasome pathway (Figure 1) is selective proteolytic degradation of proteins involved in various bio-
logical processes, including development, differentiation, proliferation, signal transduction, and apop-
tosis [3]. Because unbalanced protein homeostasis plays a vital role in the development, growth, and 
survival of malignancies [4], targeting factors involved in the synthesis and degradation of proteins 
as an anticancer strategy has been explored [5]. Increased proteasome activity has been observed in 
various cancers, such as prostate [6], colon [7], and leukemia [8], suggesting that cancer cells are more 
dependent on the ubiquitin-proteasome pathway than normal cells and that targeting this pathway in 
the treatment of human cancer is quite promising. Inhibition of the chymotrypsin (CT)-like activity of 
the tumor proteasome is associated with cell cycle arrest and induction of apoptosis [9,10], indicating 
that inhibition of the proteasome may efficiently cause selective killing/resting of cancer cells with little 
effect on normal cells but also sensitize resistant cancer cells to current chemo- or radiotherapy [11]. 
There are two steps in the ubiquitin-proteasome pathway (Figure 1) [12]: 
conjugation of multiple ubiquitin molecules to the target protein, and  •
degradation of the ubiquitin-tagged protein by the 26S proteasome.  •
The 26S proteasome is a large (2.5 MDa), multi-subunit complex that is localized in both the cytosol 
and the nucleus of cells [13-15]. The 26S proteasome is comprised of the catalytic 20S core and two 19S 
regulatory caps (Figure 1) [16,17]. The 20S core is made up of 28 subunits, arranged to form a barrel-
like structure of four alternately stacked rings: two non-catalytic alpha rings (seven subunits each) 
surrounding two catalytic beta rings (seven subunits each) [18-20]. The alpha subunits allow access to 
the proteasomal active sites only to unfolded proteins, while the beta subunits are responsible for the 
proteolytic activities of the proteasome [20]. There are three active beta subunits: beta-1, responsible 
for the caspase or peptidyl-glutamyl peptide-hydrolyzing (PGPH)-like activity, beta-2 for trypsin-like 
and beta-5 for chymotrypsin (CT)-like [20,21]. The catalytic activity of each active subunit is depen-
dent on an amino terminal Thr1 residue, a nucleophile, which can be inhibited by some proteasome 
inhibitors (such as bortezomib; Figure 2) throu-
gh interactions with electrophilic motifs within 
their structures [19, 22]. 
Also important for proper function are the six 
ATPase and at least eight non-ATPase subunits 
which are contained within the 19S regulatory 
cap (700 kDa) and are necessary for the reco-
gnition, deubiquitination, unfolding, and tran-
slocation of target proteins before degradation 
by the 20S core [23,24]. The 19S regulatory cap 
can be divided into a base and a lid, with the 
base containing the six ATPase subunits, Rpt1-
6, which form a hexameric ring [25-27] and two 
non-ATPases, Rpn-1 and -2 [28,29]. The base 
component is responsible for recognition and 
unfolding of the ubiquitinated proteins, as well 
as opening of the 20S gate and translocation of 
target substrates into the core. The lid is compo-
sed of at least six non-ATPases, which contain 
ubiquitin receptors Rpn-10/S5A and Rpn-13/
Figure 1. The ubiquitin-proteasome 
pathway
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Adrm1 [30]. The Rpn-10/S5A receptor has two ubiquitin interacting motifs which have a higher affini-
ty for poly-ubiquitinated proteins [31]. Rpn-13/Adrm1 is important in the deubiqitination of proteins, 
as it binds to the non-ATPase Rpn2 to recruit some deubiquitinating enzymes (DUBs) to the protea-
some [32-34]. Deubiquitination is a very highly regulated process which is important for recycling of 
ubiquitin molecules and controlling the rate of ubiquitin-dependent proteasomal degradation [35]. 
The ubiquitination step of the UPP is characterized by three different enzymes, E1, E2, and E3 (Figure 
1). The UPP begins with ATP-dependent E1-mediated activation of ubiquitin, a 76 amino acid protein 
that is ubiquitously expressed and serves as a tag for target proteins destined for degradation by the 
UPP (Figure 1), except in rare cases such as mODC and HIF-1α, which require no ubiquitination for 
proteasomal degradation [36-38]. Activated ubiquitin is then transferred from E1 to E2, which is re-
sponsible for ubiquitin conjugation, and to E3, the ubiquitin-ligating enzyme, which then aids in the 
transfer of active ubiquitin to lysine residues within the target protein [39,40]. The ubiquitin-tagged 
target protein is then transported to the 26S proteasome, where degradation occurs and the ubiquitin 
molecules are released for recycling (Figure 1) [41]. This tightly regulated process is crucial for the 
regulation of many cellular processes, including those involved in tumorigenesis [42], which makes it 
a promising target for anti-cancer therapeutic agents.
In addition to its critical role in protein homeostasis, the proteasome also functions in several non-
proteolytic processes. These include transcription-coupled nucleotide excision repair [43], initiation 
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and elongation of transcription [44] and regulation of gene expression [45]. The 19S regulatory subunit 
possesses chaperone-like activity that is important in efficient transcriptional elongation by remode-
ling and stabilization of RNA polymerase II and the FACT complex, which physically interact with 
the proteasome [46]. Importantly, in addition to the proteasome pathway, ubiquitin is also involved in 
membrane-trafficking, protein kinase activation, DNA repair and chromatin remodeling [47]. 
Because ubiquitin is involved in several processes, it is no surprise that there are several ubiquitin-like 
proteins (Ubls) that are structurally similar to ubiquitin and also post-translationally modify proteins in 
a pathway separate from that of ubiquitin. Two examples of Ubls include SUMO/Sentrin and NEDD8. 
SUMO (small ubiquitin-like modifier) functions in may cellular processes including cell cycle control, 
nuclear transport and responses to viral infections, and aberrant sumoylation has been implicated in va-
rious diseases [48]. There are three isoforms: SUMO-1, -2 and -3, of which -2 and -3 are essentially iden-
tical, containing a sumoylation motif around K11 which allows formation of poly-SUMO chains, and 
function differently than -1, which has no sumoylation motif and therefore cannot form chains [49,50]. 
SUMO-1 does contain an ubiquitin-homology domain that is 18% identical and 48% homologous to 
human ubiquitin and has gly-gly residues which are necessary for conjugation [51-55]. Proteins to be 
sumoylated are activated by the E1 AOS1 (28% identical/56% similar to N-terminal half of ubiquitin) 
-UBA2 (homologous to C-terminal half of ubiquitin [56-59], conjugated by the E2 UBC9 [54,60-64], 
and ligated by one of three E3 enzymes, RanBP2, PIAS, and Polycomb protein Pc2. Many protein targets 
of SUMO are involved in transcription, DNA repair and maintenance of chromatin structure and su-
moylation of these targets is modulated by acetylation and phosphorylation [48]. Interestingly, in some 
cases sumoylation seems to oppose ubiquitination. For example, ubiquitination of IκB (inhibitor of NF-
κB) leads to degradation of the protein, while sumoylation leads to stabilization [65].
Another important ubiquitin-like protein is NEDD8 (neural precursor cell-expressed developmental-
ly-downregulated), which is enriched in the nucleus and weak in the cytosol, unlike ubiquitin, which 
exists equally in the nucleus and cytosol [66]. NEDD8 is not a direct signal for degradation but a re-
gulator of E3 ubiquitin ligases and all of its known substrates are members of the cullin family of pro-
teins, which bind RING-finger proteins to recruit E2 enzymes [67-70]. NEDD8 contains a C-terminal 
glycine [66] that is activated by the E1 APPB1 (28% identical/56% similar to N-terminal half of the 
ubiquitin E1) -UBA3 (homologous to C-terminal half) [68,71-74]. Activated NEDD8 is then transfer-
red to its substrate by the E2 UBC12 [68,71,74] and its removal is dependent on the proteases USP21, 
DEN/NEDP1 and COP1. 
Importantly, like ubiquitin, these and other ubiquitin-like proteins have been implicated in the pa-
thogenesis of some human diseases, including cancer. For instance, mutations in SUMO have been 
reported in retinoblastoma and melanoma [75,76], and dysregulation has been observed in several 
other cancers, such as lung, prostate, breast, colon, brain, hepatocellular and ovarian [77-79]. Simi-
larly, NEDD8 downregulation has been reported in prostate carcinomas [80]. Therefore, due to their 
importance in normal cellular processes and apparent roles in cancer progression, these ubiquitin-like 
proteins may also serve as putative drug targets. In fact, targeting the SUMO E2 enzyme UBC9, which 
is upregulated in some human malignancies, is already being investigated [79,81].
Targeting the 20S proteasomal core
The proteasome inhibitor anticancer drug bortezomib
Properties, biological effects and mechanisms of action of bortezomib
Bortezomib, a dipeptide boronic acid derivative first synthesized in 1995 by Myogenics Company and 
called MG-341, contains pyrazinoic acid, phenylalanine and leucine in its structure (Figure 2). After 
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promising results from in vitro and in vivo studies and a small phase I clinical trial, it was renamed 
PS-341 and purchased by Millenium Pharmaceuticals. Bortezomib has demonstrated considerable 
apoptotic inducing activity in a range of tumor cell lines and animal models [82-84]. In 2003, seven 
years after it was initially synthesized, the US Food and Drug Administration approved bortezomib 
(Velcade®) for the treatment of multiple myeloma. 
The molecular formula of bortezomib is C19H25BN4O4 and its chemical IUPAC name is [3-methyl-
1-(3-phenyl-2-pyrazin-2-ylcarbonylamino-propanoyl) amino-butyl] boronic acid (Figure 2). Phase I 
clinical trials revealed that bortezomib distributes to the plasma within ten minutes of IV injection and 
is able to enter nearly all tissues except brain and adipose tissues [85-88]. Bortezomib is metabolized 
through cytochrome p450 mediated intracellular oxidative deboronation [89] and its half-life is more 
than 40 hours [87]. 
Bortezomib induces apoptosis through reversible inhibition of the 26S proteasome. Inhibited proteaso-
me activity usually recovers within 72 hours after administration [90]. Proteasome activity is inhibited 
when the boronic acid group in bortezomib binds to and forms a complex with the threonine hydroxyl 
group in the active site of the β5-subunit, which ultimately results in cell death [91]. Although success 
with bortezomib has been achieved in hematological malignancies, less than encouraging results have 
been observed in solid tumors [92,93]. In addition to its use as a single agent, the effects of bortezomib 
in combination with conventional chemotherapeutics have been investigated and the results were quite 
encouraging [94-100]. 
The results of several preclinical studies demonstrated the potency of bortezomib in vitro against human 
tumor cells and in vivo in xenograft animal models. In a standard NCI-60 screen, bortezomib was found 
to potently inhibit cell proliferation [82] and apoptosis was observed in vitro in many malignant cells 
including multiple myeloma, prostate, pancreatic, renal and squamous cell carcinomas [101-106]. Im-
portantly, the antitumor activity of bortezomib was observed in both chemoresistant and chemosensiti-
ve myeloma cells and the sensitivity of resistant cells to chemotherapy was increased significantly when 
combined with a sublethal dose of bortezomib with no effect on normal hematopoietic cells [107,108]. 
Additionally, in an in vitro study of four ovarian and three prostate cancer cell lines, bortezomib had 
comparable effects on cells derived from solid tumors and hematological malignancies [83]. Bortezomib 
was also able to potently inhibit the growth of multiple myeloma xenografts in mice [109]. 
Preclinical studies have revealed that bortezomib has multiple targets in malignant cells. One possible 
mechanism may be activation of NOXA [110]. NOXA (Latin for damage) is a pro-apoptotic member 
of the Bcl-2 family [111] and is involved in p53-mediated apoptosis. Noxa gene expression is associated 
with direct activation of its promoter by p53 [111]. Chemo- or radiotherapy-mediated apoptosis oc-
curs through upregulation of p53 and subsequent Noxa gene expression. NOXA upregulation has been 
shown to induce apoptosis through interaction with, and inhibition of the anti-apoptotic proteins Bcl-
XL and Bcl-2 or stimulation of other pro-apoptotoic factors [19,112,113]. Importantly, one study has 
shown that bortezomib treatment in myeloma and melanoma cell lines resulted in p53-independent 
induction of NOXA and blockade of NOXA induction with an antisense oligonucleotide caused only 
30% to 50% reduction in apoptosis [110]. Bortezomib can induce NOXA in a variety of tumor cell lines 
with defective p53 signaling [114], and clinical studies indicate that bortezomib can suppress tumor 
growth in a p53-independent manner [16,115]. One study has shown that bortezomib treatment in 
myeloma and melanoma cell lines resulted in p53-independent induction of NOXA and blockade of 
NOXA induction with an antisense oligonucleotide caused only 30% to 50% reduction in apoptosis 
[110]. Importantly, NOXA induction by bortezomib occurs preferentially in cancer cells compared to 
normal cells [110, 116]. While bortezomib selectively caused a 20- to 60-fold induction of NOXA in 
melanoma cells, levels were unaffected in normal melanocytes [110,116,117]. 
Reports have also suggested that suppression of the NF-κB signaling pathway may be another key 
mechanism associated with the activity of bortezomib [16]. NF-κB is a p50/p65 heterodimeric tran-
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scription factor that usually exists in an inactive form in the cytoplasm bound to its inhibitory protein, 
IκB. Upon degradation of IκB, the active NF-κB complex can translocate into the nucleus where it sti-
mulates the expression of various genes including cytokines (IL-6, TNF-α), survival factors (IAPs, Bcl-
XL), and insulin-like growth factor-I (IGF-I), which results in proliferation, resistance to apoptosis and 
drug-resistance in cancer cells [118]. In drug-resistant multiple myeloma cells that have been shown to 
express higher NF-κB activity than drug-sensitive multiple myeloma cells [107,119], bortezomib pre-
vents degradation of IκB, thus blocking NF-κB activation as well as suppressing expression of related 
cytokines and survival factors. Conversely, studies have also shown that the NF-κB may not be impor-
tant to the anti-tumor activity of bortezomib. In a study of mice bearing human multiple myeloma cel-
ls, treatment with bortezomib was associated with activation of NF-κB, rather than inhibition [120]. 
Other possible mechanisms by which bortezomib causes apoptosis include disruption of the interac-
tion between tumor cells and dendritic cells [121]; induction of endoplasmic reticulum (ER) stress and 
generation of reactive oxygen species (ROS) [122,123]; inhibition of angiogenesis in human myelo-
ma, pancreatic and squamous cell carcinoma xenografts [106,124]; induction of extrinsic and intrinsic 
apoptotic pathways via activation of caspases-8 and -9 [125,126]; and activation of the p38 mitogen-
activated protein kinase (MAPK) pathway [127]. Usually multiple targets may play important roles 
in induction of apoptosis by bortezomib in some cancer cells while different targets may be critical in 
other cells. 
Bortezomib in clinical trials
Phase I clinical trials of bortezomib
After the success achieved in preclinical studies, several clinical trials evaluating the effectiveness of 
bortezomib for the treatment of multiple myeloma in patients have been completed. In a dose-defining 
phase I trial investigating bortezomib as a single agent, bortezomib induced a dose-dependent inhibi-
tion of 20S proteasome activity from 36%, 60%, 65%, to 74%, after 1 hour treatment of bortezomib at 
0.40, 1.04, 1.20, and 1.38 mg/m2 doses, respectively [128]. The results of this study of 27 patients with 
relapsed multiple myeloma confirmed preclinical findings that bortezomib could inhibit proteasome 
activity in a dose- and time-dependent manner. The highest dose of bortezomib tested, 1.04 mg/m2, 
was well tolerated and of the nine patients that completed at least one full cycle and were assessable 
for response, one had a complete response and eight showed improvement in paraprotein levels and 
marrow plasmacytosis [128]. 
In another phase I clinical trial bortezomib was used in combination with doxorubicin (Figure 2). For-
ty-two patients with advanced hematologic malignancies were enrolled to obtain preliminary response 
data and to determine the maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs). The 
maximum tolerated dose was 1.30 mg/m2 and the most common adverse effects were fatigue (88%), 
thrombocytopenia (69%), lymphopenia (64%), nausea (64%), constipation (60%), peripheral neuro-
pathy (55%), and anemia (52%) [98]. In another clinical trial evaluating 22 multiple myeloma patients 
with a combination of bortezomib and doxorubicin, eight patients had a complete response (CR, 36%) 
or near-CR, and another eight had partial responses (PRs, 36%) [98].
Other phase I clinical trials have also investigated the effects of bortezomib either alone or in combina-
tion on solid tumors. Bortezomib as a single agent showed anti-tumor activity in patients with advan-
ced androgen-independent prostate cancer [129], and an overall response rate of 47% was observed in 
recurrent ovarian or primary peritoneal cancer after treatment with bortezomib in combination with 
carboplatin (Figure 3) [130]. No significant responses were observed in patients with aggressive meta-
static breast cancer or neuroendocrine tumors treated with bortezomib alone [38,131,132]. Similarly, 
in a study of patients with hormone refractory prostate cancer and castrate-resistant metastatic pro-
state cancer [133], no significant responses were seen after treatment with bortezomib in combination 
with either docetaxel [134] or prednisone (Figure 2) [135].
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Phase II clinical trials of bortezomib
Following the promising results of phase I trials, a large phase II trial was performed [136]. In the 
SUMMIT (Study of Uncontrolled Multiple Myeloma Managed with Proteasome Inhibition Therapy) 
trial, 202 patients with relapsed or refractory myeloma who had previously been treated were enrolled. 
Patients were treated with 1.3 mg/m2 bortezomib on days 1, 4, 8, and 11 of a 3-week cycle for as many 
as eight cycles. An overall response rate (complete response + partial response + minimal response) 
of 35%, including 4% CR, 6% with near-CR and 18% with PR, was achieved in patients treated with 
bortezomib alone [136]. In the CREST (Clinical Response and Efficacy Study of Bortezomib in the 
Treatment of Relapsing Multiple Myeloma) phase II trial, 67 patients with relapsed/refractory multiple 
myeloma were enrolled [137]. Patients were randomly divided into two groups, receiving either 1.0 or 
1.3 mg/m2 of bortezomib and anticancer activity was observed. This study showed that bortezomib 
was still effective at a dose of 1.0 mg/m2 for relapsed multiple myeloma patients with attenuating dose-
associated toxicity [137]. 
Two other phase II trials investigated the efficaciousness of bortezomib in combination with con-
ventional chemotherapeutic agents. A study of 32 patients with previously untreated symptomatic 
multiple myeloma compared the effects of bortezomib as a single agent versus in combination with 
dexamethasone (Figure 2) [11]. All patients completed the first two cycles of bortezomib alone, with 
3% of patients reaching CR, 9% near CR and 28% PR. Of the 32 patients, 22 were treated with a com-
bination of bortezomib and dexamethasone and an increased response was seen in 15 of 22 patients 
(68%) [11]. In another study, relapsed multiple myeloma patients were treated with a combination of 
bortezomib, doxorubicin and dexamethasone (Figure 2) [138]. Twenty of 21 patients (95%) achieved 
at least a partial response (PR), including CR in 43%, near-CR in 14%, very good PR in 24%, and PR 
in 14% [138]. 
Importantly, the efficacy of bortezomib against mantle cell lymphoma and non-Hodgkin’s lymphoma 
has also been investigated in phase II clinical trials. In one study of pretreated and untreated mantle 
cell lymphoma, treatment with bortezomib (1.3 mg/m2) resulted in 46.2% and 46.7% response rates, 
respectively, suggesting that bortezomib may be quite effective for the treatment of mantle cell lympho-
ma [139]. Another trial showed a 58% overall response rate after treatment with bortezomib in patients 
with indolent non-Hodgkin’s lymphoma and mantle cell lymphoma [140]. Similarly, a phase II study 
evaluating the use of bortezomib and pemetrexed (Figure 2) alone or in combination in advanced 
NSCLC that had been previously treated was also conducted. No significant response or survival ad-
vantage was observed, but bortezomib was better tolerated when given in combination with pemetre-
xed [141], and several clinical trials are being conducted to continue to explore the use of bortezomib 
as a treatment for NSCLC. Unfortunately, other studies investigating the use of bortezomib against 
solid tumors have yielded disappointing results.
Phase III clinical trials of bortezomib
Based on the results of the phase II trials, a large international phase III trial in patients with relap-
sed multiple myeloma who had received 1-3 prior therapies was performed to compare the effects of 
bortezomib with those of high-dose dexamethasone [104]. Patients (n = 669) received either 1.3 mg/
m2 bortezomib (twice weekly for 2 weeks followed by a 1 week rest; intravenously) or high-dose dexa-
methasone (40 mg orally). The combined complete and partial response rates were 38% and 18% for 
bortezomib and dexamethasone (p < 0.001), respectively, with median times to progression of 6.22 
months in the bortezomib group versus 3.29 months in the dexamethasone group. Among patients 
taking bortezomib the one-year survival rate was 80%, while that for patients taking dexamethasone 
was 66% (p = 0.003) [104]. This trial demonstrated the advantage of bortezomib treatment compared 
with dexamethasone in terms of response rate, time to progression, and survival [104]. 
The phase III APEX (Assessment of Proteasome Inhibition for Extending Remissions) study evaluated 
patients with relapsed myeloma and assessed the impact of dose-modification on the severity and re-
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versibility of peripheral neuropathy associated with bortezomib treatment [142]. After 1.3 mg/m2 bor-
tezomib for eight 21-day cycles followed by three 35-day cycles, 37% patients (124/331) had peripheral 
neuropathy that could be improved by dose modification without adverse effects on the outcome [142], 
suggesting that bortezomib-associated peripheral neuropathy is not only manageable, but also reversi-
ble in most relapsed myeloma patients. In another study of 638 patients with relapsed/refractory mul-
tiple myeloma, patients received 1.3 mg/m2 bortezomib on days 1, 4, 8, and 11 of a maximum of eight 
3-week cycles (median = 5 cycles) [143]. An overall response rate of 67%, including 11% CR, 22% near 
CR, 18% PR and minimal response in 16%, was achieved. On the day of and day after each bortezomib 
dose, 20 mg/die dexamethasone was added after completion of at least two cycles for progressive and at 
least four for stable disease. Of the 208 patients that received dexamethasone, enhanced response was 
observed in 70 patients (34%). Overall, the study showed that bortezomib, alone or in combination 
with dexamethasone, is both safe and effective for the treatment of relapsed/refractory multiple myelo-
ma in patients with prior treatment [143]. 
The efficacy of bortezomib in combination with other conventional chemotherapeutics was investiga-
ted in another phase III trial [144]. Bortezomib in combination with dexamethasone (VD) or with de-
xamethasone and lenalidomide (VRD; Figure 2) as primary first-line treatment for multiple myeloma 
was examined in this study. Patients who had received previous dexamethasone-based treatments were 
enrolled to determine if better prolonged disease control results from switching to a proteasome inhi-
bitor (VD arm) or from adding a proteasome inhibitor (VRD arm) to the current treatment. Complete 
results have not yet been published [144]. 
Another large phase III trial investigating bortezomib in combination treatments was conducted at 151 
centers in 22 countries. Multiple myeloma patients who had received no previous treatments (n = 682) 
were randomly divided into treatment groups receiving either either a combination of bortezomib plus 
melphalan-prednisone or melphalan-prednisone (Figure 2) alone [145]. This trial showed that borte-
zomib plus melphalan-prednisone may provide a valuable front-line treatment for myeloma patients 
and that the standard of care should no longer be melphalan-prednisone alone [145]. Most recently, in 
the phase III VISTA trial, combinations of bortezomib plus melphalan and prednisone compared with 
melphalan and prednisone were tested in previously untreated multiple myeloma. After prolonged 
follow-up (median 36.7 months), the data from this trial were analyzed. This follow-up not only vali-
dated the original study results, but also indicated that bortezomib-based drugs as first-line treatments 
afford greater survival advantage than treatment with conventional drugs followed by salvage with 
bortezomib-based treatments [146]. Additionally, initial treatment with bortezomib leads to lesser or 
equal amounts of resistance to subsequent therapies as compared to initial treatment with traditional 
chemotherapeutics [146]. Overall, the preclinical and clinical trials evaluating the use of bortezomib in 
vitro and in vivo have shown that the use of proteasome inhibitors as anti-cancer agents is a promising 
approach and should be further investigated.
However, although bortezomib has been used successfully in the clinic, adverse effects as well as resi-
stance have been observed, suggesting that further development of drugs like bortezomib is necessary 
in order to reduce toxicity. In fact, some second generation proteasome inhibitors, marizomib and car-
filzomib (Figure 2) [147,148] with different chemical and biochemical properties compared to borte-
zomib, have been developed in the search for novel, less toxic inhibitors. Additionally, other inhibitors 
that target the specialized immunoproteasome (Immunoproteasome-Specific Inhibitors) [148], natural 
compounds that are unable to interact with bortezomib and old copper-binding drugs may be much 
more potent with significantly less dose-limiting toxicities than some of the currently approved drugs 
[149]. Use of these novel inhibitors may also overcome bortezomib resistance or sensitize resistant 
tumor cells to bortezomib treatment, which could potentially result in dramatically increased success 
in the clinic.
Use of proteasome inhibitors in anticancer therapy
267Reviews in Health Care 2011; 2(4)© SEEd All rights reserved
S. M. Schmitt, L. Lu, Q. P. Dou
Disulfiram-copper complexes as proteasome inhibitors
Due to the importance of several metals to normal cellular function, the use of compounds that can 
bind important biological metals may be useful in the treatment of cancer. Some of these compounds, 
such as dithiocarbamates, have already been approved for the treatment of other ailments, and preclini-
cal studies have proven their potential usefulness as anti-cancer agents. Some of these metal complexes 
have potent proteasome-inhibitory activities in cancer cells.
Metals in cancer development and therapy
The discovery that metals like copper and zinc are altered in tumors led to extensive research regarding 
the roles of these metals in the development and progression of human cancers as well as their potential 
as anti-cancer therapeutics. High serum and tissue levels of copper have been reported in several tumor 
types including colon [150], lung [151], prostate [150,152], breast [153,154] and brain [155]. Studies 
have shown a role for copper as a co-factor in angiogenesis through its ability to induce VEGF mRNA 
transcription as well as protein expression [156,157]. These studies led to the investigation of copper 
chelators for anti-angiogenic therapy in cancer treatment regimens [158,159].
Zinc, like copper, plays a key role in cellular processes, including defense against free radicals and proli-
feration [43-44] as well as being structurally important to several proteins and enzymes [160,161]. Zinc 
has also been implicated in apoptosis, but this role appears complex and cell-type specific [162-165]. 
Additionally, studies have shown an association between altered Zn levels and systemic abnormalities 
such as cancer [166], though this, like its role in apoptosis, appears cell-type specific and a firm rela-
tionship between zinc levels and tumor development has not yet been established [164,167,168]. 
Copper and zinc are not only essential to criti-
cal biological processes such as tumorigenesis, 
but they have also been investigated as possible 
anticancer targets and as metal centers in anti-
cancer drugs, especially following the discovery 
that some metal-based compounds, such as ci-
splatin (Figure 3), possess potent anti-cancer 
properties. Since its discovery, over 90% of te-
sticular cancer cases have been cured by cispla-
tin, and it has also been important in the treat-
ment of several other types of cancer, including 
bladder, cervical, head and neck, lymphoma, 
melanoma and ovarian [169]. Cisplatin causes 
apoptosis via its interaction with DNA and for-
mation of adducts which interfere with replica-
tion and transcription [170]. After thorough 
investigation, a (Pt)-GG intrastrand cross-link 
has been found to be responsible for the cytoto-
xicity of cisplatin [171]. Unfortunately, the toxi-
cities and drug resistance, both intrinsic and 
acquired, associated with cisplatin have hinde-
red its widespread clinical use [172, 173]. The 
success and limitations of cisplatin have spur-
red the search for new, less-toxic metal-based 
complexes, employing Cu, Zn, Ga, Au, Sn and 
many other metals, as well as second generation 
platinum drugs like carboplatin (Figure 3). In 
Figure 3. Structures of cisplatin, carboplatin, 
disulfiram and copper gluconate. Cisplatin 
has been used for decades to successfully 
treat testicular cancer. Carboplatin is a 
second-generation platinum drug that has 
been used in combination with bortezomib 
in clinical trials. Disulfiram is a copper 
chelator and is currently in clinical trials in 
combination with copper gluconate
268 Reviews in Health Care 2011; 2(4) © SEEd All rights reserved
Use of proteasome inhibitors in anticancer therapy S. M. Schmitt, L. Lu, Q. P. Dou
designing these putative drugs, keeping in mind important properties that may affect the activities of 
these compounds is important. For example, activity is not solely governed by the presence of the metal 
itself, but can also be influenced by the oxidation state, number and type of ligand bound, and the co-
ordination geometry of the complex. Other important properties that can play a role in the activity of 
metal complexes include kinetic lability, redox behavior, and electric charge/radius ratio. The functio-
nal importance of metals, such as copper and zinc, to normal cellular homeostasis coupled with the 
success of metal-containing chemotherapeutics has resulted in studies investigating chelation of these 
vital metals with metal-chelators. One example of metal-chelating compounds is dithiocarbamates, 
which include several drugs that have been previously approved for use in the treatment of various 
diseases, including bacterial and fungal infections, AIDS, and alcoholism [174-176]. Taking advantage 
of the approval of drugs used to treat different conditions which have also been shown to function as 
metal chelators is an exciting concept in the field of cancer drug development and design. Previously 
approved drugs, such as disulfiram (DSF, Figure 3), that may form metal complexes with copper and 
zinc, have been explored as potential proteasome inhibitors that may serve as novel anticancer agents. 
Preclinical data with DSF 
Disulfiram (tetraethylthiuram disulfide, DSF) (Figure 3) is an irreversible inhibitor of aldehyde de-
hydrogenase, and is one of only two US FDA-approved drugs for the treatment of alcoholism [177-
179]. DSF contains an R1R2NC (S)SR3 functional group, with sulfhydryl groups that can react with 
Cu(II) [180]. This DSF-Cu reaction was confirmed by color-change experiment when DSF and CuCl2 
were mixed at a 1:1 ratio [181]. While DSF is not able to interact with other bioavailable metals such as 
Fe (II or III) or Mn (III) [180], studies have shown that DSF is able to bind Zn(II). One report demon-
strated that Zn(II) supplementation potentiated DSF treatment in melanoma and hepatic cancer [182] 
and our lab has found that DSF-Zn complex can inhibit the proteasome, albeit at a weaker potency 
than DSF-Cu. Importantly, studies have also shown that during its absorption into the gastrointestinal 
system, DSF is promptly converted to its copper complex [177].
We have reported that DSF when complexed with Cu could potently inhibit both purified 20S prote-
asome (IC50 = 7.5 µM) and intact 26S proteasome in MDA-MB-231 breast cancer cell lysates (20 µM). 
Inhibition of CT-like activity by > 95% and proliferation by up to 85% was observed in cells treated 
with DSF-Cu. We also showed increased ubiquitinated protein levels, as well as apoptosis-related PARP 
cleavage and morphological changes [181]. Not surprisingly, DSF alone had no obvious effects in cul-
tured cells, which do not contain high levels of copper, but enhanced response was observed in breast 
cancer cells cultured in copper-enriched medium. Importantly, DSF had no effects on normal breast 
MCF-10A cells, suggesting a lack of toxicity and a strategy that takes advantage of the increased copper 
levels observed in human tumor tissues as an anti-tumor mechanism [181].
Our lab has also shown that disulfiram effectively inhibits the proteasome in vivo. We reported signi-
ficant tumor growth inhibition (74%) in female athymic nude mice bearing MDA-MB-231 xenografts 
treated with 50 mg/kg DSF daily for 30 days. A significant decrease in chymotrypsin-like activity (87%) 
and associated accumulation of Bax, p27 and ubiquitinated proteins were apparent and increases in 
caspase-3 activity and PARP cleavage associated with apoptosis induction were also observed [181]. 
Clinical trials with DSF
Importantly, a phase I study investigating the toxicity profile and safety of DSF in combination with 
copper gluconate (Figure 3) in refractory malignancies with liver metastases (NCT00742911; Hunts-
man Cancer Institute) is currently recruiting patients. Another phase I/II clinical trial evaluating the 
effects of DSF in stage IV metastatic melanoma patients has been completed, but results are not yet 
available (NCT00256230; UC-Irvine). One study is recruiting patients to examine the effects of DSF 
on PSA levels in recurrent prostate cancer patients (NCT01118741; Johns Hopkins University). Two 
additional trials are investigating the efficacy of DSF in combination treatments. One is currently re-
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cruiting multiple myeloma patients with one previous treatment and will assess response rate and du-
ration following treatment with DSF and arsenic trioxide (NCT00571116; UC-Irvine). Though results 
are unavailable, another study, determining the effects of addition of DSF to current chemotherapeutic 
treatments in patients with non-small cell lung cancer, has been completed (NCT00312819; Hadassah 
Medical Organization). Overall, these results suggest a potential novel approach for the treatment of 
human malignancies that utilizes the ability of DSF to chelate cellular copper.
Natural compounds as proteasome inhibitors
Natural products have recently received considerable attention in the search for more efficacious, less 
toxic chemotherapeutic agents. Several studies have revealed the potent chemopreventive and thera-
peutic effects of some natural compounds and as a result, various plant polyphenols have been investi-
gated as potential anti-cancer agents. 
Green tea polyphenols
Derived from the Camellia sinensis plant, tea is the most popular beverage in the world after water. There 
are many varieties of tea, including black, oolong, and green, all containing many beneficial compounds. 
The most potent of these are polyphenols, chemical substances characterized by the presence of more 
than one phenol group per molecule and believed to provide the coloring in many plants [183].
(-)-EGCG in preclinical studies
The most active polyphenol in tea, (-)-epigallocatechin-3-gallate, or (-)-EGCG (Figure 4), has been 
shown to possess anticancer activity in several types of cancer [184-186]. The chemopreventive activi-
ties of (-)-EGCG are probably due to its effects on signal transduction, inhibition of angiogenesis and 
stabilization or activation of tumor suppressor genes, such as p53 [187-189]. A recent pilot study inve-
stigating the effects of green tea on premalignant prostate lesions revealed that green tea significantly 
reduced the incidence of prostate cancer development, with only 3% of patients treated with green tea 
developing cancer, compared with 30% of the placebo-treated group [190]. A case-control study in 
China showed that the risk of prostate cancer is inversely related to frequency, duration, and quantity 
of green tea consumption [191] and in another study, post-treatment prevention of cancer occurred in 
patients consuming at least five cups per day, as compared to those consuming fewer than four [192]. 
Importantly, a recent study in multiple myeloma has revealed a direct interaction between (-)-EGCG 
and bortezomib (Figures 4 and 1, respectively), inhibiting the efficacy of bortezomib, suggesting that 
green tea consumption should be limited during bortezomib therapy [193]. 
Studies in our lab have revealed the potent proteasome-inhibiting ability of (-)-EGCG in vivo and in 
vitro. (-)-EGCG inhibited the chymotrypsin-like activity in purified 20S proteasome (IC50 = 86-194 
nM), as well as the 26S proteasome in Jurkat leukemia, LNCaP and PC-3 prostate cancer, and MCF-7 
breast cancer cell extracts. Associated with this inhibition, increased levels of ubiquitinated proteins, 
p27, and IκB-α were also observed [194]. Interestingly, the concentrations of (-)-EGCG found in the 
serum of green tea drinkers are sufficient to cause inhibition of proteasomal activity [194]. We also 
reported that the ester bond within (-)-EGCG is important to its inhibitory activity [194]. Additionally, 
although (-)-EGCG is quite potent, it is unstable in neutral or alkaline physiological conditions. Thus, 
we synthesized several new (-)-EGCG analogs with –OH groups removed from the B- and/or D-rings, 
as well as their acetate-protected prodrugs (Figure 4), to discover more stable polyphenol proteasome 
inhibitors. We observed that decreasing the number of –OH groups from the B- or D-ring resulted in 
decreased proteasome inhibitory activity in vitro, but the protected prodrugs inhibited CT-like activity 
by up to 97% [195], as well as inhibiting proliferation and inducing apoptosis more potently than (-)-
EGCG in several cancer cell lines [196]. Conversion to and accumulation of (-)-EGCG also occurred 
in Pro-EGCG (Figure 4) treated cells [197], and this conversion was confirmed in Jurkat leukemia cells 
by HPLC analysis [197]. Treatment of mice bearing MDA-MB-231 xenografts with Pro-EGCG resulted 
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in more significant suppression of tumor growth, proteasome inhibition, and induction of apoptosis 
as compared with (-)-EGCG treatment [197]. Thus, Pro-EGCG increases bioavailability, stability, and 
anticancer efficacy of (-)-EGCG in human breast cancer cells and tumors, suggesting that Pro-EGCG 
may be a promising agent for the prevention and treatment of cancer. 
Our lab has also investigated the effects of methylation on (-)-EGCG, and based on a case-control study 
suggesting decreased cancer-protection by methylated polyphenols, we hypothesized that methylation 
would decrease proteasome-inhibition by green tea polyphenols. We synthesized and tested methyla-
ted (-)-EGCG and (-)-ECG analogs that can be found in vivo [198]. Adding one methyl group resulted 
in decreased proteasome inhibition, and inhibitory strength further decreased with the addition of 
more methyl groups. Jurkat T cells were also treated with methylated peracetate-protected analogs, and 
the effects were similar to those in purified 20S proteasome; the more highly methylated analogs were 
less effective [198]. Therefore, proteasome inhibition mediated by green tea polyphenols is suppressed 
by methylation, ultimately reducing the cancer-preventive effects of these tea polyphenols.
(-)-EGCG in clinical trials
Some phase I and II clinical trials using (-)-EGCG (Figure 4) and other green tea polyphenols have 
been completed. One phase I study investigated the optimal dose and tolerability of (-)-EGCG in chro-
nic lymphocytic leukemia (CLL) patients [199]. Thirty-three previously untreated, asymptomatic CLL 
patients were given Polyphenon E (doses = 400-2000 mg) and observed for maximum tolerated dose 
and adverse effects. Maximum tolerated dose was not achieved and only two patients experienced dose 
limiting toxicities including dysphagia and abdominal discomfort (distention, nausea, flatulence). 
Other adverse effects were mild and considered non-dose limiting [199]. Only one patient reached 
partial response (PR), but other clinical effects were observed, including 11 patients (33%) with sustai-
ned ≥20% reduction in absolute lymphocyte count (ALC) and in 12 patients with palpable adenopathy, 
11 experienced at least 50% reduction after (-)-EGCG treatment. This study showed that (-)-EGCG is 
tolerable and can induce reduction of ALC in patients with CLL, and resulted in a phase II study that 
began in November 2007 [199]. Another phase I study evaluated the effects of (-)-EGCG supplemen-
tation on serum levels of prostate cancer biomoarkers [200]. Twenty-six patients scheduled for radical 
prostatectomy after positive prostate biopsies took Polyphenon E (containing 800 mg (-)-EGCG) daily 
until time of surgery. Serum samples taken prior to Polyphenon E treatment and on the day of prosta-
tectomy were tested by ELISA for hepatocyte growth factor (HGF), vascular endothelial growth factor 
Figure 4. Structures of natural compounds used as proteasome inhibitors: Green tea polyphenol 
(-)-epigallocatechin gallate or (-)-EGCG, its more potent prodrug Pro-EGCG, and the dietary 
flavonoid apigenin
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(VEGF), insulin-like growth factor (IGF)-I, IGF binding protein-3 (IGFBP-3), and prostate-specific 
antigen (PSA) [200]. Cancer-associated fibroblasts were also treated with (-)-EGCG and analyzed for 
protein and mRNA levels of HGF and VEGF and liver function enzymes were monitored to measure 
toxicity. All prostate cancer-associated biomarkers decreased significantly after treatment with no ele-
vation of liver function enzymes. Protein and mRNA levels of HGF and VEGF in cancer-associated 
fibroblasts also decreased. Together, these results indicate that even short-term (-)-EGCG treatment 
may be beneficial in the treatment or prevention of prostate cancer [200]. 
To study the bioavailability and metabolism of green tea polyphenols in prostate tissue, a clinical trial 
of 17 men with localized prostate cancer was completed. Eight patients drank six cups of green tea 
daily for three to six weeks prior to radical prostatectomy, while the remaining nine patients drank 
water [201]. Prostate tissue was analyzed by HPLC, identifying 4”-O-methyl EGCG (4”-MeEGCG) 
and EGCG in comparable amounts and (-)-epicatechin-3-gallate in lower amounts in men consuming 
green tea (38.9 ± 19.5, 42.1 ± 32.4, and 17.8 ± 10.1 pmol/g tissue, respectively) and no polyphenols 
were observed in the tissues of men consuming water [201]. Interestingly, in the urine of patients who 
consumed green tea, 50-60% of both primary polyphenols [(-)-epigallocatechin and (-)-epicatechin] 
existed in methylated form. Additionally, LNCaP cells treated with (-)-EGCG were able to methylate 
(-)-EGCG to 4”-MeEGCG, a form that is much less potent at inhibiting proliferation and inducing 
apoptosis than its unmethylated form [201]. These data show that following brief green tea treatment, 
both methylated and unmethylated EGCG are detectable in prostate tissue and that methylation status 
may affect the activity of (-)-EGCG.
In addition to the completed clinical trials, a number of phase I and II trials investigating the effects 
of (-)-EGCG are currently recruiting patients or have begun and are ongoing. Some of these studies 
are investigating the effects of (-)-EGCG treatment on various types of cancer, including nonmetasta-
tic bladder, breast, cervical, colorectal, prostate, non-small cell lung and uterine carcinomas as well 
as multiple myeloma. Two other studies are evaluating the effects of (-)-EGCG in combination with 
EGFR-inhibitor erlotinib in patients with non-small cell lung cancer and premalignant lesions of the 
head and neck. Finally, still others are examining the preventive effects of (-)-EGCG in patients at risk 
for cervical, esophageal and lung cancers. The preclinical and clinical data, as well as the large number 
of recruiting/ongoing clinical trials, clearly suggest a great potential for (-)-EGCG as a chemopreven-
tive and therapeutic agent.
Apigenin
Apigenin (5,7,4-trihydroxyflavone; Figure 4), a dietary flavonoid found in a variety of natural products 
including celery seed, chamomile flowers, grapes, and parsley [202-205] has also been shown to pos-
sess antioxidant, antimutagenic and chemopreventive properties. Although the mechanism is not fully 
understood, chemoprevention by apigenin has been reported in several cancers such as cervical [206], 
lung [207], prostate [208] and skin [209]. 
Preclinical studies of apigenin
Studies in our lab have shown that the carybonyl carbon (C4 position) of apigenin (Figure 4) could 
bind to the β5 subunit in an orientation suitable for nucelophilic attack by the N-terminal Thr1 [210]. 
We reported that apigenin potently inhibits chymotrypsin-like activity in purified 20S proteasome 
(IC50=1.8-2.3 µM) and intact 26S proteasome in Jurkat leukemia cell lysates (1-10 µM) [210], but not in 
immortalized, non-transformed natural killer cells, suggesting that apigenin exerts its activity with lit-
tle to no toxicity in healthy cells [210]. We also observed proteasome inhibition-associated accumula-
tion of ubiquitin-tagged proteins as well as apoptosis-associated morphological changes, caspase-3/-7 
activation and PARP cleavage. Similar proteasome inhibition and apoptosis induction were observed 
in breast cancer MBA-MD-231 cells and tumors (up to 40% inhibition at highest dose) treated with 
apigenin [211]. Treatment of female nude mice bearing MDA-MB-231 breast cancer xenografts with 
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apigenin at two different doses (25 µM and 50 µM) resulted in 43% tumor growth inhibition following 
treatment with the higher dose and importantly, no significant changes in body weight were observed 
between treatment groups, indicating the low toxicity of this compound [211].
Clinical trials of apigenin
Results of preclinical studies have led to some clinical trials examining the efficacy of apigenin (Figure 
4) in human patients. One prospective study investigated the association between flavonol and flavo-
noid (including apigenin) consumption in the diet and cancer risk [212]. Food-intake questionnaires 
were analyzed to assess the intake of flavonols/flavonoids in 3234 female cancer patients identified 
during 11.5 year follow-ups. Unfortunately, no significant associations were observed, indicating that 
the flavonols/flavonoids tested have little preventive activity [212].
The results of another prospective study were more promising, suggesting a possible role for dietary 
intake of flavonoids like apigenin in reducing the risk of colorectal cancer [213]. In this study of 87 pa-
tients, 36 had resected colon cancer and 51 had undergone polypectomy. Participants were divided into 
two groups with one receiving a flavonoid mixture [20 mg apigenin + 20 mg (-)-EGCG] and the other 
serving as a matched control group [213]. While none of the patients with resected colon cancer trea-
ted with flavonoid mixture (n = 14) developed recurrence and only one developed adenoma, of the 15 
untreated controls, recurrence occurred in three (20%) and adenoma in four (27%). Overall combined 
recurrence rates were 7% (1/14) and 47% (7/15) in treated and untreated patients, respectively [213]. 
The results of clinical studies clearly show that further investigation into the preventive and therapeutic 
effects of apigenin are necessary before any concrete conclusions are reached.
Targeting the upstream factors E1, E2 and E3
While targeting the catalytic 20S core has received considerable attention in the field of drug develop-
ment, there are other factors in the ubiquitin-proteasome pathway, such as the upstream E1, E2 and 
E3 enzymes involved in ubiquitin conjugation. In fact, inhibitors of each of these enzymes have been 
identified and investigated in the preclinical setting. While it was initially believed that inhibiting the 
ubiquitin E1 would be lethal, the identification of two natural E1 inhibitors has suggested that this 
may indeed be a viable strategy for the treatment of human cancers. Panepophenanthrin and himeic 
acid (Figure 5) have both been shown to specifically inhibit the formation of E1-ubiquitin thioester 
intermediates, with no activity toward the SUMO-1 E1 protein [214,215]. Additionally, a synthetic 
pyrazone derivative, PYR-41 (Figure 5), with E1-inhibitory activity has been developed that prevents 
degradation of proteins as well as cytokine-mediated activation of NF-κB, and activates p53 to cause 
cell death [216]. 
Importantly, inhibition of the E2 enzymes has also been explored, following the observation that fun-
ctional knockdown of the E2 Ubc13 resulted in increased p53 activity [217]. Reports have shown that 
a natural compound, leucettamol A (Figure 5), is able to inhibit the interaction of the E2 Ubc13 with 
the inactive conjugating enzyme variant Uev1A, which is required for efficient poly-ubiquitin chain 
formation [218].
Inhibition of ubiquitin E3 ligases may be one of the more widely researched and successful strategies for 
targeting upstream ubiquitin-proteasome pathway factors, probably due in part to their role in identi-
fying target proteins for ubiquitination. The E3 family is divided into three classes, RING, HECT and 
U-box, based on domain structure and mechanisms of target recognition. Because it is frequently ove-
rexpressed in human cancers, the p53-specific RING-type E3 MDM2/HDM2 is a popular target for 
inhibition, which may lead to reactivation of p53 and resultant apoptosis [219]. For example, the MDM2 
small molecule inhibitor nutlin-3 (Figure 5) suppresses tumor progression in mouse xenograft models 
[220], suggesting that MDM2 is a promising target. More recently, the combination of nutlin-3 with bor-
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tezomib was shown to result in additive and synergistic cytotoxic effects in bortezomib-sensitive mul-
tiple myeloma and in epithelial carcinoma cells, respectively [221]. In addition, some natural products, 
such as chlorofusin and (-)-hexylitaconic acid (Figure 5), have been identified that inhibit the interac-
tion between MDM2 and p53 [222-225]. Moreover, disulfiram and its derivatives were able to inhibit 
zinc finger- and RING-finger-containing ubiquitin E3 ligases [226]. Thus, inhibition of ubiquitination is 
a very viable strategy that should be further investigated for the treatment of human cancers.
Targeting the 19S regulatory subunit
The success achieved with inhibitors of the 20S catalytic core suggests that inhibition of proteasomal 
regulators may also be very promising, as this inhibition should only hinder some proteasomal fun-
ctions. Indeed, the ATPase subunits contained within the base of the 19S regulatory cap have proven 
good drug targets. After screening of a library of purine analog-capped peptoids, RIP-1 (Regulatory 
Particle Inhibitor Peptoid-1; Figure 6) was identified as an inhibitor of protein unfolding through tar-
geting of the ATPase Rpt4 [227, 228]. Ubiquitin-chain receptors have also been investigated as putative 
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Figure 5. Structures of inhibitors of upstream factors of the ubiquitin-proteasome pathway. E1 
inhibitors: panepophenanthrin, himeic acid and PYR-41; E2 inhibitor: leucettamol A; E3 inhibitors: 
nutlin-3, (-)-hexylitaconic acid and chlorofusin
274 Reviews in Health Care 2011; 2(4) © SEEd All rights reserved
Use of proteasome inhibitors in anticancer therapy S. M. Schmitt, L. Lu, Q. P. Dou
targets and reports have indicated that ubistatin A (Figure 6) blocks recruitment of ubquitinated pro-
teins to the 26S proteasome by binding the ubiquitin chains, ultimately suppressing proteasome-me-
diated proteolysis [229]. Clearly, factors that regulate the 20S catalytic core are good drug targets and 
further investigation into this strategy would be very worthwhile. 
Conclusions and future directions
The importance of the ubiquitin-proteasome pathway to cellular homeostasis as well as the discovery that 
malignant cells exhibit increased proteasome activity have prompted investigation into the possibility that 
this pathway may be a promising target for cancer therapeutics. Current standard of care for most cancers 
include surgery, chemotherapy and radiotherapy, and targeting the ubiquitin-proteasome pathway may 
reduce the toxicity associated with current chemotherapeutics or radiation. The clinical use of proteasome 
inhibitors has been validated by the FDA approval of bortezomib for the treatment of multiple myeloma 
and mantle cell lymphoma. However, some toxicity and resistance has been associated with bortezomib 
treatment, stimulating the search for less toxic proteasome inhibitors. This search has resulted in many 
preclinical and clinical studies investigating the efficacy of drugs currently approved for other diseases as 
well as natural compounds, which should display lower toxicity and resistance than bortezomib. 
Disulfiram, an anti-alcoholism drug approved by the FDA, can chelate intracellular copper, resulting 
in proteasome inhibition and associated cellular death. The success of disulfiram in vitro and in vivo 
Figure 6. Structures of 19S regulatory subunit Inhibitors RIP-1 and ubistatin A
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has also led to clinical trials investigating disulfiram both alone and in combination. Some natural 
compounds including the green tea polyphenol (-)-EGCG and the flavonoid apigenin are also proven 
proteasome inhibitors. These compounds potently induce apoptosis in several cancer types in vitro and 
in vivo and have also been shown to possess chemopreventive activities. Clinical trials using (-)-EGCG 
have yielded very promising results, while those using apigenin have been inconsistent and further 
studies are necessary. Using natural compounds to sensitize resistant tumors to chemotherapy/radio-
therapy has been well documented and the use of novel natural compounds to sensitize bortezomib-
resistant tumors is an important field of research in which we and many others are involved. 
The overwhelmingly positive results achieved with proteasome inhibitors clearly demonstrate that tar-
geting the ubiquitin-proteasome pathway is a viable strategy for anti-cancer treatment and prevention. 
The use of these compounds in combination with current chempotherapeutics may also be very effecti-
ve, especially against drug-resistant tumors. Other promising directions include inhibitors against enzy-
mes involved in ubiquitin conjugation and ligation, which would act early in the ubiquitin-proteasome 
pathway (Figure 1) and could specifically target many cancer-related proteins, as well as 19S regulators 
of the 20S core, which would block entry of proteins into the core for degradation. Indeed, several po-
tential upstream inhibitors have already been identified. Additionally, the various roles for ubiquitin-
like proteins such as SUMO and NEDD8 indicate that inhibition of these proteins may also be a viable 
strategy. Thus, targeting the ubiquitin-proteasome pathway, through both direct inhibition of the 20S 
proteasome and inhibition of necessary ligases 
and regulatory proteins, remains a promising 
strategy in the treatment of human cancers.
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Questions for further research
Further clinical studies are necessary to 
prove the chemosensitizing properties of 
natural compounds and copper-binding 
compounds. More importantly, phase III 
clinical trials must be completed in order 
for some of these compounds to achieve 
widespread clinical use.
The review in brief
Clinical Problem The current standard of care for cancer treatment includes surgery, chemotherapy and radiotherapy. 
These treatments are often accompanied by severe side effects and resistance and recurrence rate is 
generally high.
Outcomes Bortezomib, disulfiram, (-)-EGCG and apigenin are potent proteasome inhibitors and apoptosis 
inducers as well as chemosensitizers in cancers.
Clinical Relevance Targeting the tumor ubiquitin-proteasome pathway is a promising strategy in anticancer therapy. 
Using existing drugs and natural compounds may help reduce toxicity and resistance associated with 
current chemotherapies. 
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